The U.S. Court of Appeals for the Seventh Circuit agreed with a district court earlier this week that neither a settlement agreement between AbbVie and a number of generic biologics companies, nor the 132 patents owned by Abbvie covering its blockbuster drug, Humira, violate the Sherman Antitrust Act. This holding, which is significant in its own right, also has broader implications for patent-antitrust analysis.
Recent Posts
- $300 Million Damages Ruling for Optis Wiped Out by Federal Circuit Over Jury Instructions Violating Apple’s Seventh Amendment Rights
- Congress and Courts Need to Look in the Mirror When Asking Why Medical Innovation is Declining
- USPTO Hiring Freeze Ends, Patent Examiners Wanted
- Judiciary Committee Votes Squires Through 20-2
- Disney and Universal Become Latest to Sue Midjourney Over Generative AI Service